Moyer J D, Malinowski N, Cysyk R L
Eur J Cancer Clin Oncol. 1986 Mar;22(3):323-7. doi: 10.1016/0277-5379(86)90398-6.
The inhibition of uridine utilization by 3-deazauridine, an inhibitor of uridine kinase, and by dipyridamole, an inhibitor of the facilitated transport of nucleosides was examined. 3-Deazauridine (500 mg/kg) markedly inhibited (greater than 70%) the formation of uracil nucleotides from uridine in liver, kidney, and L1210 tumor cells. The degree of inhibition is greatly reduced by 6 hr after administration of the drug. Dipyridamole (100 mg/kg) did not significantly reduce salvage of uridine by liver or kidney and produced only small, transient reductions in salvage by L1210 tumors. Dipyridamole pretreatment did not alter the rate of clearance of uridine from the plasma.
研究了尿苷激酶抑制剂3-去氮尿苷以及核苷易化转运抑制剂双嘧达莫对尿苷利用的抑制作用。3-去氮尿苷（500毫克/千克）显著抑制（超过70%）肝脏、肾脏和L1210肿瘤细胞中尿苷形成尿嘧啶核苷酸的过程。给药6小时后，抑制程度大幅降低。双嘧达莫（100毫克/千克）并未显著降低肝脏或肾脏对尿苷的补救合成，仅使L1210肿瘤的补救合成产生轻微、短暂的降低。双嘧达莫预处理并未改变尿苷从血浆中的清除速率。
